4.965

8.36% -0.475

Camp 4 Therapeutics Corp (CAMP)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CAMP Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$5.44

Aprire:

$5.76

Volume 24 ore:

421.33K

Relative Volume:

1.97

Capitalizzazione di mercato:

$312.99M

Reddito:

$3.50M

Utile/perdita netta:

$-80.40M

Rapporto P/E:

-1.9311

EPS:

-2.5711

Flusso di cassa netto:

$-29.83M

1 W Prestazione:

+18.13%

1M Prestazione:

+34.37%

6M Prestazione:

+22.78%

1 anno Prestazione:

+198.50%

Intervallo 1D:

$4.95

$6.00

Intervallo di 1 settimana:

$4.12

$6.00

Portata 52W:

$1.41

$7.75

Camp 4 Therapeutics Corp Stock (CAMP) Company Profile

Nome

Camp 4 Therapeutics Corp

Settore

Healthcare (1088)

Industria

Biotechnology (604)

Telefono

617-651-8867

Indirizzo

ONE KENDALL SQUARE, CAMBRIDGE, CA

Dipendente

Cinguettio

@calamp

Prossima data di guadagno

2026-08-13

Ultimi documenti SEC

CAMP's Discussions on Twitter

Compare CAMP vs VRTX, REGN, ARGX, RVMD, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CAMP Camp 4 Therapeutics Corp	4.9877	341.38M	3.50M	-80.40M	-29.83M	-2.5711
VRTX Vertex Pharmaceuticals Inc	514.14	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	811.04	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	994.68	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	211.54	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	359.54	39.31B	5.76B	514.49M	1.10B	4.4813

Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-04-14	Iniziato	Rodman & Renshaw	Buy
2025-10-02	Iniziato	Cantor Fitzgerald	Overweight
2025-09-16	Downgrade	JP Morgan	Overweight → Neutral
2025-05-27	Iniziato	Wedbush	Outperform
2024-11-05	Iniziato	JP Morgan	Overweight
2024-11-05	Iniziato	Piper Sandler	Overweight
2024-11-05	Iniziato	William Blair	Outperform
2022-08-16	Aggiornamento	Craig Hallum	Hold → Buy
2021-12-22	Downgrade	Craig Hallum	Buy → Hold
2021-09-24	Reiterato	Craig Hallum	Buy
2021-06-25	Reiterato	Craig Hallum	Buy
2020-12-18	Downgrade	JP Morgan	Neutral → Underweight
2020-04-17	Aggiornamento	Jefferies	Hold → Buy
2020-03-05	Reiterato	Craig Hallum	Buy
2019-12-20	Reiterato	Craig Hallum	Buy
2019-12-20	Downgrade	First Analysis Sec	Outperform → Neutral
2019-06-28	Aggiornamento	Northland Capital	Market Perform → Outperform
2019-05-29	Downgrade	Goldman	Neutral → Sell
2019-05-01	Reiterato	Craig Hallum	Buy
2019-03-25	Downgrade	JP Morgan	Overweight → Neutral
2019-01-25	Aggiornamento	JP Morgan	Neutral → Overweight
2018-12-21	Aggiornamento	Craig Hallum	Hold → Buy
2018-12-14	Reiterato	B. Riley FBR	Buy
2018-12-11	Downgrade	First Analysis Sec	Strong Buy → Outperform
2018-12-11	Downgrade	Northland Capital	Outperform → Market Perform
2018-11-27	Iniziato	Goldman	Neutral
2018-10-15	Iniziato	Jefferies	Hold
2018-09-28	Reiterato	Craig Hallum	Hold
2018-04-27	Reiterato	Craig Hallum	Hold
2018-03-08	Downgrade	Craig Hallum	Buy → Hold
2018-02-16	Aggiornamento	First Analysis Sec	Equal-Weight → Overweight

Mostra tutto

Camp 4 Therapeutics Corp Borsa (CAMP) Ultime notizie

Aug 16, 2026

ETFs Investing in CAMP4 Therapeutics Corporation Stocks - TradingView

Aug 16, 2026

Aug 14, 2026

Balyasny group discloses 4.99% Camp4 Therapeutics (CAMP) position with warrant blocker - Stock Titan

Aug 14, 2026

Aug 13, 2026

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Aug 13, 2026

CAMP4 Q2 Loss Widens to $33.5M; EPS Misses Estimates - scanx.trade

Aug 13, 2026

CAMP4 Therapeutics (Nasdaq: CAMP) widens loss as derivative liability surges - Stock Titan

Aug 13, 2026

CAMP4 Therapeutics (CAMP) widens Q2 2026 loss, boosts cash runway to 2028 - Stock Titan

Aug 13, 2026

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights - The Manila Times

Aug 13, 2026

Camp4 Therapeutics Corp SEC Filing (Aug 13, 2026) - Stock Titan

Aug 13, 2026

Aug 11, 2026

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Recommendation of "Moderate Buy" by Analysts - marketbeat.com

Aug 11, 2026

Aug 10, 2026

Trails Edge reports 6% Camp4 Therapeutics stake (CAMP) totaling 3.79M shares - Stock Titan

Aug 10, 2026

CAMP4 Therapeutics Corp expected to post a loss of 21 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 06, 2026

Camp4 Therapeutics Corp CEO to launch new SYNGAP1 clinical trial in upcoming initiative - tradersunion.com

Aug 06, 2026

Aug 05, 2026

Yuri Maricich Acquires 6,551 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock - MarketBeat

Aug 05, 2026

CAMP4 Therapeutics (NASDAQ:CAMP) CEO Josh Mandel-Brehm Purchases 6,551 Shares - MarketBeat

Aug 05, 2026

Richard Young Buys 16,378 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock - marketbeat.com

Aug 05, 2026

Insider Buying: CAMP4 Therapeutics (NASDAQ:CAMP) CFO Buys $10,809.15 in Stock - marketbeat.com

Aug 05, 2026

5AM Ventures group updates CAMP4 Therapeutics (CAMP) stake and warrant terms - Stock Titan

Aug 05, 2026

Aug 04, 2026

CAMP4 closes $50.1 million second tranche of private placement By Investing.com - Investing.com India

Aug 04, 2026

CAMP4 Therapeutics Secures $50 Million Private Financing - TipRanks

Aug 04, 2026

Camp4 Therapeutics Raises $50.1 Million in Second Closing of Private Placement - TradingView

Aug 04, 2026

CAMP4 Therapeutics (Nasdaq: CAMP) raises $50.1M in second private placement closing - Stock Titan

Aug 04, 2026

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement - GlobeNewswire

Aug 04, 2026

Aug 01, 2026

Camp4 Therapeutics Corp leverages regulatory RNA to target genetic root causes - Traders Union

Aug 01, 2026

Jul 30, 2026

SummitTX Capital L.P. Invests $1.50 Million in CAMP4 Therapeutics Corporation $CAMP - marketbeat.com

Jul 30, 2026

Jul 29, 2026

CAMP4 Therapeutics Corporation Revenue Breakdown – NASDAQ:CAMP - TradingView

Jul 29, 2026

Jul 28, 2026

CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Forecasts - Yahoo! Finance Canada

Jul 28, 2026

Analysts Are Bullish on These NA Stocks: SpaceX (SPCX), CAMP4 Therapeutics Corporation (CAMP) - The Globe and Mail

Jul 28, 2026

Camp4 Moves Into Human Trials -- The Upside Is Underpriced (NASDAQ:CAMP) - Seeking Alpha

Jul 28, 2026

Jul 27, 2026

CAMP4 receives Australian clearance for SYNGAP1 therapy trial By Investing.com - Investing.com UK

Jul 27, 2026

CAMP4 THERAPEUTICS CORPORATION (CAMP) stock price, news, quote and history - Yahoo Finance UK

Jul 27, 2026

Camp4 Therapeutics’ lead ASO approved for clinical trials in Australia - BioWorld News

Jul 27, 2026

CAMP4 receives Australian clearance for SYNGAP1 therapy trial - Investing.com Australia

Jul 27, 2026

Camp4 Therapeutics Corp secures clinical trial approval for first SYNGAP1 disease-modifying therapy in Australia - Traders Union

Jul 27, 2026

CAMP4 Therapeutics (CAMP) clears CMP-002 trial in Australia, eyes $50.1M raise - Stock Titan

Jul 27, 2026

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder - globenewswire.com

Jul 27, 2026